Microbot Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory pro

Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke

global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization

Mass., September 8, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within the interventional

radiology community for its LIBERTY Robotic System, today announced the newest appointment to its Scientific Advisory

Board (SAB), Sebastian Flacke, M.D. The addition of this thought leader adds a key robotic pioneer, who has a history of contributing

to the development and commercialization of novel medical device products.

Flacke is a proven innovator in the robotics field and has pioneered new solutions for his patients in interventional radiology, specifically

the endovascular space," commented Harel Gadot, Chairman, CEO, and President. "We expect the addition of Dr. Flacke is further

evidence that we are establishing the right scientific team to help guide Microbot through the regulatory process and transform the market

with the first fully disposable endovascular robotic system that will enable access to multiple patients and users globally."

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms

provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for

patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available

at http://www.microbotmedical.com.

to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or

prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that

contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential

products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies,

any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct the SCS's early feasibility

study which could adversely affect or delay such study, uncertainty in the results of pre-clinical and clinical trials or regulatory

pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance

of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors"

in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's

web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required